Lv7
3680 积分 2021-08-25 加入
Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding
24天前
已完结
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer
24天前
已完结
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
24天前
已完结
Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer across distinct immunohistochemistry statuses
27天前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
1个月前
已完结
[Consensus on clinical diagnosis and treatment of breast cancer with low expression and ultralow expression of HER-2 (2025 edition)]
2个月前
已完结
Prediction of survival after de-escalated neoadjuvant therapy in HER2+ early breast cancer: A pooled analysis of three WSG trials
3个月前
已关闭
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
5个月前
已完结
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer
5个月前
已完结
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01
5个月前
已完结
皖公网安备34019202002308
